Themis Medicare Posts FY26 Standalone Net Loss of ₹14.19 Crore, Recommends ₹0.50 Dividend

Themis Medicare Ltd has reported a standalone net loss of ₹14.19 crore for the financial year ended March 31, 2026. This compares to a profit of ₹23.92 crore in the previous fiscal year.

Reader Takeaway: Operational decline and one-time charges led to a FY26 loss, yet a dividend is proposed.

What just happened

Themis Medicare Ltd announced its financial results for the fiscal year 2025-26. On a standalone basis, the company registered a net loss of ₹14.19 crore. This is a significant downturn from the standalone profit of ₹23.92 crore reported for FY25. Revenue from operations also saw a decrease, falling to ₹342.24 crore in FY26 from ₹405.51 crore in FY25.

The company's consolidated total income for FY26 stood at ₹351.60 crore, with a consolidated profit attributable to equity holders amounting to ₹1.14 crore.

Why this matters

For investors, the shift from standalone profitability to a net loss in FY26 is a key concern. The decline in revenue indicates potential challenges in the company's core business operations or market conditions. However, the Board's recommendation of a final dividend of ₹0.50 per equity share (50%) is a positive signal, suggesting management's confidence in maintaining shareholder returns despite the bottom-line performance.

The backstory

The company's performance in FY26 was affected by exceptional items. These included a ₹0.87 crore impact from Labour Codes and a ₹1.29 crore write-off related to investments in a wholly-owned subsidiary. These one-time charges contributed to the reported net loss.

What changes now

Investors will be closely watching the company's strategy to reverse the standalone loss and improve revenue in the upcoming financial year. The effectiveness of operational improvements and the absence of similar exceptional items in the future will be crucial for performance recovery. The dividend, if approved, will provide a small return to shareholders.

Risks to watch

The primary risk is the continuation of declining revenues and standalone profitability. Management's ability to address operational inefficiencies and market challenges will be critical. The impact of future regulatory changes and subsidiary management will also need monitoring.

Peer comparison

Information on specific peer performance for FY26 in the pharmaceutical sector is not provided in the filing. Generally, the pharmaceutical sector is competitive, with companies focusing on R&D, market penetration, and cost management.

Context metrics (time-bound)

Standalone Revenue from Operations: FY26 ₹342.24 crore vs. FY25 ₹405.51 crore.
Standalone Profit/(Loss): FY26 ₹-14.19 crore vs. FY25 ₹23.92 crore.

What to track next

Investors should monitor quarterly results for signs of revenue growth and improved standalone profitability. Management commentary on strategies to address the FY26 performance and the impact of exceptional items will be important. The final dividend payout is subject to shareholder approval.